Hostname: page-component-7b7567c8c-jswmv Total loading time: 0 Render date: 2026-11-15T13:06:59.133Z Has data issue: false hasContentIssue false
  • English
  • Français

Stress axis dysfunction in schizophrenia

Published online by Cambridge University Press:  16 April 2020

S. Yeap and
J.H. Thakore
S. Yeap
Affiliation:
Neuroscience Center, St. Vincent's Hospital, Richmond Road, Dublin 3, Ireland
J.H. Thakore*
Affiliation:
Neuroscience Center, St. Vincent's Hospital, Richmond Road, Dublin 3, Ireland
*
**Corresponding author. E-mail address: jthakore@rcsi.ie (J.H. Thakore)
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

StressSchizophreniaHypothalamic-pituitary-adrenal axis

Information

Type
Research Article
Information
European Psychiatry , Volume 20 , Issue S3 , October 2005, pp. S307 - S312
Copyright
Copyright © Elsevier SAS 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Abel, K., O'Keane, V., Murray, R., Cleare, A.Serotonergic function and negative and depressive symptomatology in schizophrenia and major depression. Psychoneuroendocrinology 1997; 22: 539–548CrossRefGoogle ScholarPubMed
Aleem, A., Kulkarni, A., Yeragani, V.Dexamethasone suppression test, schizophrenia and movement disorder. Acta Psychiatr Scand 1998; 78: 689–694CrossRefGoogle Scholar
Aleman, A., Hijman, R., de Haan, E. et al. Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 1999; 156: 1358–1366Google ScholarPubMed
Armanini, M., Hutchins, C., Stein, B. et al. Glucocorticoid endangerment of hippocampal neurons is NMDA-receptor dependent. Brain Res 1990; 532: 7–12CrossRefGoogle ScholarPubMed
Axelrod, J., Reisine, T.Stress hormones: their interaction and regulation. Science 1984; 224: 452–459CrossRefGoogle ScholarPubMed
Axelson, D., Doraiswamy, P., McDonald, W. et al. Hypercortisolaemia and hippocampal changes in depression. Psychiatry Res 1993; 47: 163–173CrossRefGoogle Scholar
Banki, C., Bisette, G., Arato, M. et al. CSF corticotrophin-releasingfactor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 1992; 144: 873–877Google Scholar
Beebington, P., Bowen, J., Hirsch, S., Kuipers, E.Schizophrenia and psychosocial stresses. In: Hirsch, S.R., Weinberger, D.R.(Eds.), Schizophrenia, Blackwell Science, Cambridge, 1995, pp. 587–604Google Scholar
Brier, A., Buchanan, R.The effects of metabolic stress on plasma progesterone in healthy volunteers and schizophrenic patients. Life Sci 1992; 52: 1527–1534CrossRefGoogle Scholar
Callicott, J., Egan, M., Bertolino, A. et al. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol Psychiatry 1998; 44: 941–950CrossRefGoogle ScholarPubMed
Chalmers, D., Kwak, S., Mansour, A., Akil, H., Watson, S.Corticosteroids regulate brain hippocampal 5-HT1A receptor mRNA expression. J Neurosci 1993; 13: 914–923CrossRefGoogle ScholarPubMed
Christie, J., Whalley, L., Dick, H., Blackwood, D., Blackburn, I., Fink, G.Raised plasma cortisol concentration, a feature of drug-free psychotics and not speficis for depression. Br J Psychiatry 1986; 148: 58–65CrossRefGoogle Scholar
Condren, R., Thakore, J.Cushing's disease and melancholia. Stress 2001; 4: 91–119CrossRefGoogle ScholarPubMed
Cotter, D., Pariante, C.Stress and the progression of the developmental hypothesis of schizophrenia. Br. J. Psychiatry 2002; 181: 363–365CrossRefGoogle ScholarPubMed
Crossin, K., Tai, M., Krushel, L. et al. Glucocorticoid receptor pathways are involved in the inhibition of astrocyte proliferation. Proceedings of the National Academy of Sciences of the USA 1997; 94:2687–2692CrossRefGoogle ScholarPubMed
Davis, K., Khan, R., Ko, G. et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474–1486Google ScholarPubMed
Davies, L., Arentzen, R., Reid, J. et al. Glucocorticoid sensitivity of vasopressin mRNA levels in the paraventricular nucleas of the rat. Proc Natl Acad Sci USA 1996; 83:1145–1149CrossRefGoogle Scholar
Deicken, R., Pegues, M., Amend, D.Reduced hippocampal Nacetylaspartate without volume loss in schizophrenia. Schizophre Res 1998; 82: 53–61Google Scholar
De Kloet, E., Vreugdenhill, E., Oitzl, M., Joels, M.Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998; 19: 269–301Google ScholarPubMed
De Leon, M., McRae, T., Tsai, J. et al. Abnormal cortisol response in Alzheimers disease linked to hippocampal atrophy [letter]. Lancet 1988; 2: 391–392CrossRefGoogle Scholar
Diamond, D., Fleshner, M., Rose, G.Psychological stress repeatedly blocks hippocampal primed burst potentiation in behaving rats. Behav Brain Res 1994; 62: 1–9CrossRefGoogle ScholarPubMed
Duval, F., Mokrani, M., Monreal, J., Bailey, P., Valdebenito, M., Crocq, M., Macher, J.Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests. Psychoneuroendocrinology 2003; 28: 627–642CrossRefGoogle ScholarPubMed
Eberwine, J., Jonassen, J., Evinger, M. et al. Complex transcriptional regulation by glucocorticoids and corticotrophin-releasing hormone of propiomelanocortin gene expression in rat pituitarycultures. DNA Cell Biol 1987; 6: 483–492Google Scholar
Evans, D., Burnett, G., Nemeroff, C.The dexamethasone suppression test in the clinical setting. American Journal of Psychiatry 1983; 140: 586–589Google ScholarPubMed
Fletcher, P.The missing link: a failure of fronto-hippocampal integration in schizophrenia. Nat Neurosci 1998; 1: 266–267CrossRefGoogle Scholar
Fowles, D.Schizophrenia: stress-diathesis revisited. Annu Rev Psychol 1992; 43: 303–336CrossRefGoogle Scholar
Gil-Ad, I., Dickerman, Z., Amdusky, S., Laron, Z.Diurnal rhythm of plasma beta endorphin, cortisol and growth hormone in schizophrenia as compared to control subjects. Psychophramacology 1998; 88: 496–499Google Scholar
Green, M.What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996; 153: 321–330Google Scholar
Heckers, S., Raunch, S., Goff, D. et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci 1998; 1: 318–323CrossRefGoogle Scholar
Hinson, J.Panacrine control of adrenocortical function: a new role for the medulla?. J Endocrinol 1990; 124: 7–9CrossRefGoogle Scholar
Hoff, A., Sakum, M., Wieneke, M., Horon, R., Kushner, M., DeLIsi, L.Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry 1999; 156: 1336–1341Google ScholarPubMed
Holmes, M., French, K., Seckl, J.Modulation of serotonin and corticosteroid receptor gene expression in the rat hippocampus with circadian rhythm and stress. Mol Brain Res 1995; 28: 186–192CrossRefGoogle ScholarPubMed
Holsboer-Trachsler, E., Buol, C., Wiedemann, K. et al. Dexamethasone suppression test in severe schizophrenic illness: effects of plasma dexamethasone and caffeine levels. Acta Psychiatrica Scandinavica 1997; 75: 608–613CrossRefGoogle Scholar
Holsboer, F.The endocrinology of mental disease. In: Grossman, A.(Ed.), Clinical Endocrinology. Blackwell Science, Oxford, pp. 1096–1116Google Scholar
Ismail, K., Murray, R., Wheeler, M. et al. The dexamethasone suppression test in schizophrenia. Psychological Medicine 1998; 28:311–7CrossRefGoogle Scholar
Jacobsen, L., Giedd, J., Costellanos, F., Vaituzis, A., Hamburger, S., Kumra, S., Lenane, M., Rapaport, J.Progressive reduction in temporal lobe structures in childhood-onset schizophrenia. Am J Psychiatry 1998; 155: 678–685CrossRefGoogle ScholarPubMed
Jacobson, L., Sapolsky, R.The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev 1991; 12: 118–134CrossRefGoogle ScholarPubMed
Jeste, D., Lohr, J.Hippocampal pathologic findings in schizophrenia: a morphometric study. Arch Gen Psychiatry 1989; 46: 1019–1024CrossRefGoogle ScholarPubMed
Jonssan, S., Luts, A., Guldberg-Kjaer, N. et al. Pyramidal neuron size in the hippocampus of schizophrenics correlates with total cell count and degree of cell disarray. Eur Arch Psychiatry Clin Neurosci 1999; 249: 169–173Google Scholar
Kahn, R., Davidson, M., Siever, L., Sevey, S., Davis, K.Clozapine treatment and its effects on neuroendocrine responses induced by the serotonin agonist m-chlorophenylpiperazine. Biol Psychiatry 2002; 26: 935–938Google Scholar
Kaneda, Y., Fujii, A., Ohmori, T.The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 935–938CrossRefGoogle ScholarPubMed
Kaneko, M., Toloyama, F., Hoshino, Y. et al. Hypothalamic-pituitaryadrenal axis function in chronic schizophrenia: association with clinical features. Neuropsychobiology 1992; 25: 1–7CrossRefGoogle Scholar
Kemali, D., Maj, M., Galderisi, S., Ariano, M., Cesarelli, M., Milici, N., Salvati, A., Valente, A., Volpe, M.Clinical and neuropsychological correlates of cerebral ventricular enlargement in schizophrenia. J Psychiatr Res 1985; 19: 587–596CrossRefGoogle Scholar
Keller-Wood, M., Dallman, M.Corticoid inhibition of ACTH secretion. Endrocr Rev 1984; 5: 1–24CrossRefGoogle ScholarPubMed
Lammers, C., Garcia Boreguero, D., Schmider, J. et al. Combined dexamethasone/corticotrophin releasing hormone test in patients with schizophrenia and in normal controls. Biol Psychiatry 1995; 38: 803–807CrossRefGoogle Scholar
Lawrie, S., Whalley, H., Byrne, M. et al. Brain structure change and psychopathology in subjects at high risk of schizophrenia. Schizophrenia Research 2000; 41:11CrossRefGoogle Scholar
Legros, J., Gazzotti, T., Carvelli, T., Fanchimont, P., Timsit-Barthier, M., von Frenckell, R., Ansseau, M.Apomorphine stimulation of vasopressin and oxytocin neurophysins: evidence for increased oxytocinergic and decreased vasopressinergic function inschizophrenics. Psychoneuroendocrinology 1992; 17: 611–617CrossRefGoogle Scholar
Linkowski, P., Geenan, V., Kerkhofs, M., Mendlewicz, J., Legros, J.Cerebrospinal fluid neurophysins in affective illness and in schizophrenia. Eur Arch Psychiatry Neurol Sci 1984; 234: 162–165CrossRefGoogle Scholar
Lundblad, J., Roberts, J.Regulation of propiomelanocortin gene expression in pituitary. Endocr Rev 1998; 9: 135–158CrossRefGoogle Scholar
Malaspina, D., Perera, G., Lignelli, A., et al.SPECT imaging of odor identification in schizophrenia. Psychiatry Res 1998; 82: 53–61CrossRefGoogle Scholar
Mauri, M., Sinforiani, E., Bono, G. et al. Memory impairment in Cuchings Disease. Acta Neurol Scand 1993; 87: 52–55CrossRefGoogle ScholarPubMed
McEwen, B., Brinton, R., Sapolsky, R.Glucocorticoid receptors and behaviour: implications for the stress response. Adv Exp Med Biol 1988; 245: 35–45CrossRefGoogle ScholarPubMed
McEwen, B., De Kloet, E., Roatene, W.Adrenal steroid receptors and actions in the nervous system. Physiol Rev 1986; 66: 1121–1188CrossRefGoogle ScholarPubMed
McEwen, B., Stellar, E.Stress and the individual. Mechanisms leading to disease. Arch Int Med 1993; 153: 2093–2101CrossRefGoogle ScholarPubMed
McEwen, B.Stress and the hippocampus: an update on current knowledge. Presse Med 1991; 20: 1801–1806Google ScholarPubMed
Meltzer, H.The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 1992; 160: 22–29CrossRefGoogle Scholar
Newcomer, J., Faustman, W., Whiteford, H., et al.Symptomatology and cognitive impairment associate independently with postdexamethasone cortisol concentrations in unmedicated schizophrenicpatients. Biol Psychiatry 1991; 29: 855–864CrossRefGoogle Scholar
Norman, R., Malla, A.Stressful life events and schizophrenia: a review of the research. Br J Psychiatry 1993; 62: 161–166CrossRefGoogle Scholar
Pariante, C., Miller, A.Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49: 391–404CrossRefGoogle ScholarPubMed
Pariante, C.M., Vassilopoulou, K., Velakoulis, D., Phillips, L., Soulsby, B., Wood, S.J., Brewer, W., Smith, D.J., Dazzan, P., Yung, A.R., Zervas, I.M., Christodoulou, G.N., Murray, R., McGorry, P.D., Pantelis, C.Pituitary volume in psychosis. Br J Psychiatry 2004; 185: 5–10CrossRefGoogle ScholarPubMed
Pantellis, C., Velakoulis, D., Suckling, J. et al. Left medial temporal lobe volume reduction occurs during the transition from high risk to first episode psychosis. Schizophrenia Research 2000; 41:35CrossRefGoogle Scholar
Purdon, S., Jones, B., Stip, E. et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzepine, risperidone, or haloperidol.. Arch Gen Psychiatry 2000; 57: 249–258CrossRefGoogle ScholarPubMed
Rao, L., Kolsch, H.Effects of estrogen on brain development and neuroprotection—implications for negative symptoms in schizophrenia. Psychoneuroendocrinology 2003; 28: 83–96CrossRefGoogle Scholar
Risch, S., Lewine, R., Kaline, N., Jewart, R., Risby, E., Caudle, J., Stipetic, M., Turner, J., Eccard, M., Pollard, W.Limbic-hypothamalmic-pituitaryadrenal axis activity and ventricular-to-brain ratio studies in affective illness and schizophrenia. Neuropsychopharmacology 1992; 6: 95–100Google Scholar
Roy, A., Pickar, D., Doran, A. et al. The corticotrophin releasing hormone stimulation test in chronic schizophrenia. Am J Psychiatry 1986; 143: 1393–1397Google ScholarPubMed
Ryan, M., Sharifi, N., Condren, R., Thakore, J.Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology 2004; 29: 1065–1070CrossRefGoogle ScholarPubMed
Sapolsky, R., Krey, L., McEwen, B.The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endrocr Rev 1986; 7: 284–301CrossRefGoogle ScholarPubMed
Sapolsky, R.Stress, glucocorticoids, and the damage to the nervous system: the current state of confusion. Stress 1996; 1: 1–11CrossRefGoogle ScholarPubMed
Sapolsky, R.The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biological Psychiatry 2000; 48: 755–765CrossRefGoogle ScholarPubMed
Sapolsky, R., Meaney, M., McEwen, B.The development of the glucocorticoid receptor system in the rat limbic brain. III. Negative-feedback regulation. Brain Res 1985; 350: 169–173CrossRefGoogle ScholarPubMed
Sharma, R., Pandey, G., Janicak, P. et al. The effect of diagnosis and age on the DST: a metaanalytic approach. Biological Psychiatry 1998; 24: 555–568CrossRefGoogle Scholar
Sucheki, D., Nelson, D., Van Oers, H. et al. Activation and inhibition of the hypothalamic-pituitary-adrenal axis of the neonatal rat: effects of maternal deprivation. Pschoneuroendocrinology 1995; 20: 169–182CrossRefGoogle Scholar
Tandon, R., Mazzara, C., DeQuardo, J. et al. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biological Psychiatry 1991; 29: 953–964CrossRefGoogle ScholarPubMed
Todtenkopf, M., Benes, F.Distribution of glutamate decarboxylase 65 immunoreactive puncta on pyramidal and nonpyramidal neurons in hippocampus of schizophrenic brain. Synapse 1998; 29: 323–3323.0.CO;2-7>CrossRefGoogle ScholarPubMed
Van Canter, E., Linkowski, P., Kerhofs, M., Hubain, P., L'Hermite-Baleriaux, M., Leclerq, R. et al. Circadian and sleep related endocrine rhythms in schizophrenia. Arch Gen Psychiatry 1991; 48: 348–356CrossRefGoogle Scholar
Walker, E., Diforio, D.Schizophrenia: a neural diathesis-stress model. Psychol Rec 1997; 104: 667–685CrossRefGoogle ScholarPubMed
Walsh, P., Spelman, L., Shariff, N., Thakore, J.H.Male patients with paranoid schizophrenia have greater ACTh and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology 2005; 30: 431–437CrossRefGoogle ScholarPubMed
Webster, M., O'Grady, J., Orthmann, C. et al. Decreased glucocorticoid receptor mRNA levels in individuals with depression, bipolar disorder and schizophrenia. Schizophrenia Research 2000; 41: 111CrossRefGoogle Scholar
Weinberger, D.Cell biology of the hippocampul formation in schizophrenia. Biol Psychiatry 1999; 45: 395–402CrossRefGoogle Scholar
Wik, G.Effects of neuroleptic treatment on cortisol and 3-methoxy-4-hydroxyphenylethyl glycol levels in blood. J Endocrinol 1995; 144: 425–429CrossRefGoogle ScholarPubMed
Wright, I., Rabe-Hasketh, S., Woodruff, P. et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000; 157: 16–25CrossRefGoogle Scholar
Yehuda, R., Southwick, S., Nussbaum, G. et al. Low urinary cortisol excretion in patients with posttraumatic stress disorder. J Nerv Ment Dis 1990; 178: 366–369CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.